dc.contributor.author | Chabanon, RM | |
dc.contributor.author | Soria, J-C | |
dc.contributor.author | Lord, CJ | |
dc.contributor.author | Postel-Vinay, S | |
dc.date.accessioned | 2019-06-04T09:47:36Z | |
dc.date.issued | 2019-01-01 | |
dc.identifier.citation | Molecular & cellular oncology, 2019, 6 (2), pp. 1585170 - ? | |
dc.identifier.issn | 2372-3556 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3248 | |
dc.identifier.eissn | 2372-3556 | |
dc.identifier.doi | 10.1080/23723556.2019.1585170 | |
dc.description.abstract | Loss of excision repair cross-complementation group 1 (ERCC1), frequently found in lung cancer, and mutations in breast cancer type 1/2 susceptibility genes (BRCA1/2), often found in ovarian, breast and prostate cancers, confer sensitivity to poly-(ADP-ribose) polymerase inhibitors (PARPi). Our work, and that of others, shows that PARPi selectively trigger tumor cell-autonomous immune phenotypes in ERCC1- or BRCA-defective contexts. This suggests that PARPi, used in appropriately selected populations, might mediate their therapeutic effects by potentiating anti-tumor immunity. | |
dc.format | Electronic-eCollection | |
dc.format.extent | 1585170 - ? | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | TAYLOR & FRANCIS INC | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | Beyond DNA repair: the novel immunological potential of PARP inhibitors. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2019-02-18 | |
rioxxterms.versionofrecord | 10.1080/23723556.2019.1585170 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | |
rioxxterms.licenseref.startdate | 2019-01 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Molecular & cellular oncology | |
pubs.issue | 2 | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Gene Function | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Gene Function | |
pubs.publication-status | Published | |
pubs.volume | 6 | |
pubs.embargo.terms | No embargo | |
icr.researchteam | Gene Function | |
dc.contributor.icrauthor | Lord, Christopher | |